A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
about
CixutumumabNovel agents for advanced pancreatic cancerInsulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant diseaseProgress of molecular targeted therapies for prostate cancersTargeting insulin and insulin-like growth factor signaling in breast cancerTargeting the insulin-like growth factor pathway in hepatocellular carcinomaHeterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibodyOptical imaging probes in oncologyIGF-IR Targeted Therapy: Past, Present and FutureCompounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cellsMolecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapymTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktMining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injuryInhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupA phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesExpression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cellsThe type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technologyInsulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Directing traffic in neural cells: determinants of receptor tyrosine kinase localization and cellular responses.Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivityIGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicityAntibody phage display libraries: contributions to oncology.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesDual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3
P2860
Q24609058-11E04F64-8B85-4AD4-AAD8-5D4C165D3AA3Q26787087-3BCE909C-D722-4564-AD35-519433417633Q26800001-1DE58367-9562-4F6D-942B-8DB939621F0FQ26823014-6633368C-CF7D-4883-B26C-B0EAD9534872Q26826380-54E8BE43-1864-4177-A1C5-BFECCD45078EQ27006846-96663C93-8181-4AB5-8DF0-AE6350CEAFF0Q27306977-B491A406-8E74-4236-A1A9-49D038A08AAAQ28067824-22F33A11-780B-4E93-B80C-705B004C47A4Q28082127-2CCAE834-8B65-422D-9EA2-91A3B52EB455Q28468664-E40F3276-5E44-4A37-98AA-6E4FD3F31AEFQ28535227-AAA16376-CDF4-479E-BBDA-703AC4ABFB15Q29547767-1301310A-02AD-4BC7-9349-460C8CD8E946Q30478475-3061535A-5C6A-488F-9725-59102D639D20Q31028788-28805D7E-6362-4560-9AA4-5CB0B211FADFQ33391425-1A629738-CC3E-41B8-BD55-8FBBF13F218FQ33398810-2C31B500-18AA-464D-9EDB-9D1B0788B061Q33407185-DEE79351-F90A-4702-B162-A3C33C1CCEC7Q33408460-3F2DC83B-7661-429A-A3B3-C093924E03BCQ33500359-3F7CFF9B-AAE4-42D4-8884-18E320EAF7A6Q33559468-FA0AB9E7-3819-4A5C-87C8-518FB94D0E93Q33611056-C3A77E8D-F42F-4DC8-B908-42646918498AQ33642235-7157B5F0-C556-4057-A71D-963E715AE45DQ33745823-2199CA02-409E-4C3A-96FD-C934491BC51CQ33889089-A837F3E6-6193-4258-9856-9F6869C737CDQ33890792-3F786BD8-337A-41BE-9D57-C0C789D3E136Q33911148-25E16C29-3F16-4079-A2FE-BEC98B3EEAD1Q33934670-49AECAF2-6DC0-403E-BA5B-1D92CB95A9C4Q34070890-91290538-5E3C-4C54-B756-C72972435EF0Q34102411-4DD67E6D-0FBF-49E1-819C-B38D7DB32477Q34130987-48232443-8B40-42AB-AFFB-44DDE099018BQ34133760-4F20F831-9638-40A3-ACB0-398D8661E327Q34159954-9998CEE5-16F5-4AD9-BE18-B8F42041A0EEQ34182483-57E41F21-6849-4B8C-BC78-744AF3509873Q34212771-9F66191E-41E4-4B35-AC33-DE452A0C1EFFQ34323991-6FF97223-D73B-496A-90CE-67C585DB55E5Q34336988-FA19E486-6AC3-466F-9BD1-902BF03870B3Q34406479-86AC7E2B-3035-44C0-81A5-1898BD2A3217Q34442002-DEEE1F92-45D7-4404-A1A1-52238BD24E5DQ34612359-26694209-5000-40A7-BEE9-A1C2CD55BF45Q34659512-A576818C-E13B-4F82-BF4D-A820ACF87408
P2860
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@ast
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@en
type
label
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@ast
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@en
prefLabel
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@ast
A fully human monoclonal antib ...... ts human tumor growth in vivo.
@en
P2093
P1433
P1476
A fully human monoclonal antib ...... its human tumor growth in vivo
@en
P2093
Andrea T Hooper
Dale L Ludwig
Daniel J Hicklin
Daniel S Pereira
Danielle Johnson
Donna Marie Anderson
Douglas Burtrum
Larry Witte
P304
P407
P577
2003-12-01T00:00:00Z